NCCN 20th Annual Conference Will Highlight 20 Years of Cancer Treatment Improvements and Explore Value in Oncology; New and Updated NCCN Guidelines®
Approximately 1,500 oncology stakeholders are expected to attend NCCN’s 20th Annual Conference: Advancing the Standard of Cancer Care™, March 12 – 14, 2015, in Hollywood, Florida.
FORT WASHINGTON, PA — The National Comprehensive Cancer Network ® ( NCCN ®) will host its 20th Annual Conference: Advancing the Standard of Cancer Care ™, March 12 – 14, 2015, at The Diplomat in Hollywood, Florida. Approximately 1,500 physicians, nurses, pharmacists, and other oncology stakeholders and representatives of the business sector are expected to attend.
“NCCN is pleased to present its 20th Annual Conference, which features an agenda comprising a multitude of experts throughout the oncology landscape, as well as exciting new developments in more than 15 cancer types and emerging therapies,” said Robert W. Carlson, MD, Chief Executive Officer, NCCN. “This year’s conference is a true testament to the magnitude of impact NCCN and its Member Institutions have had on the treatment of cancer care over the past two decades.”
On Thursday, March 12, in recognition of NCCN’s 20th Anniversary, 20 Years of Improving Cancer Care Together – An NCCN Roundtable Discussion , will feature a panel of NCCN leadership—past and present—as well as other stakeholders who have had a significant impact on the development, progression, and success of NCCN over the years. Moderated by Clifford Goodman, PhD, The Lewin Group, the roundtable will comprise discussion of noteworthy historical accomplishments, as well as the impact NCCN has had and continues to have on the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Panelists include Al B. Benson III, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University ; Dr. Carlson; Timothy J. Eberlein, MD, Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine ; David McFadden, MS, RPh, Gilead Sciences, Inc.; Lee N. Newcomer, MD, MHA, UnitedHealthcare; Samuel M. Silver, MD, PhD, University of Michigan Comprehensive Cancer Center ; Mary Lou Smith, JD, MBA, Research Advocacy Network; and Robert C. Young, MD, RCY Medicine.
Two additional roundtables are scheduled for Friday, March 13, and Saturday, March 14. On Friday, NCCN will present Value-Based Decision-Making at the Bedside. This roundtable will explore the different tools, such as clinical guidelines and pathways, and the impact such tools have on clinician and patient decision-making at the bedside. Moderated by Dr. Goodman, Thursday’s roundtable includes panelists, Peter B. Bach, MD, MAPP, Memorial Sloan Kettering Cancer Center ; Stephen B. Edge, MD, Baptist Cancer Center; Linda House, RN, BSN, MSM, Cancer Support Community; Jennifer Malin, MD, Wellpoint/Anthem; and James L. Mohler, MD, Roswell Park Cancer Institute .
The final roundtable, What are the Characteristics of an Optimal Clinical Practice Guideline? , will be held Saturday. Moderated by F. Marc Stewart, MD, Fred Hutchinson Cancer Research Center / Seattle Cancer Care Alliance , this third roundtable will cover the process through which the NCCN Guidelines are created. Panelists include David S. Ettinger, MD, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ; Michael Kuettel, MD, MBA, PhD, Roswell Park Cancer Institute; Joan S. McClure, MS, NCCN; Mary Lou Smith, JD, MBA, Research Advocacy Network; and Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center.
In addition to expert panels, this year’s conference will feature a new, customizable format in which attendees can select track sessions; presentations include the latest treatment advances for a variety of tumor types, including, but not limited to bladder, breast, colorectal, esophageal, non-small cell lung, kidney, and prostate cancers, as well as melanoma and hematologic malignancies.
The newest addition to the library of NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ®)—the NCCN Guidelines® for Smoking Cessation—will be introduced. The NCCN Guidelines for Smoking Cessation provides detailed pharmacotherapy and behavioral therapy recommendations for people with cancer who smoke.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 25 of the world’s leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.
The NCCN Member Institutions are: Fred and Pamela Buffett Cancer, Omaha, NE; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.
Katie Kiley Brown, NCCN